News
-
GlaxoSmithKline has announced that the FDA has approved its Flonase fluticasone propionate nasal spray for the treatment of allergic rhinitis for over-the-counter sale. The approval is for a 50 mcg spray, the same as the… Read more . . .
-
Canadian pharmaceutical company Milestone Pharmaceuticals, which is developing an intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia, has announced the appointment of Francis Plat as Chief Medical Officer. Dr. Plat commented,… Read more . . .
-
Lightlake Therapeutics has announced that it filed an investigational new drug application for its intranasal naloxone therapy for the reversal of opioid overdose. The company also said that it has received additional funding from the… Read more . . .
-
CD-adapco has announced that STAR-CCM+ v9.04, the latest release of its simulation software, includes new physics models useful for development and analysis of various types of OINDPs in addition to offering significantly faster operation. The… Read more . . .
-
GlaxoSmithKline and Theravance have announced the commencement of a Phase 3 study of a triple combination inhaled therapy delivered using the Ellipta DPI for the treament of COPD. The triple therapy combines fluticasone furoate (FF),… Read more . . .
-
GlaxoSmithKline has announced that the Australian Therapeutic Goods Administration (TGA) has approved the Incruse Ellipta umeclidinium DPI for the treatment of COPD. Incruse Ellipta was approved in Canada and in Europe in April 2014 and… Read more . . .
-
The UK National Health Service Prescription Services has apologized for mistakenly classifying two versions of the Relvar Ellipta fluticasone/vilanterol DPI under the wrong British National Formulary (BNF) code in its database. The two products involved… Read more . . .
-
According to Kentucky-based AntiOp, the company has received Fast Track designation from the FDA for its intranasal naloxone for the reversal of opioid overdose. The company is co-developing the unit-dose nasal spray, its only product,… Read more . . .
-
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has announced that it will acquire PecFent fentanyl nasal spray manufacturer Archimedes Pharma for £230 million in cash. Archimedes, which is based in Reading, UK, received European marketing… Read more . . .
-
Teva has announced that the FDA has accepted its new drug application for an albuterol dry powder inhaler for the treatment of asthma in patients aged 12 and older. In October 2013, Teva indicated that… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan